Advertisement

Activated Clotting Time for Heparin Dosage Monitoring in Continuous Arteriovenous Hemofiltration

  • K. Koorejian
  • R. H. Bartlett
  • J. London

Abstract

The main purpose of heparinization in continuous arteriovenous hemofiltration (CAVH) is to prevent the hemofilter from clotting without having to systemically anticoagulate the patient. As with any extracorporeal circuit, when blood comes in contact with a foreign surface, protein is absorbed within milliseconds and platelet adhesion occurs. The more fibrinogen that attaches to the circuit, the greater the affinity for platelets. When platelets attach to the surface, they activate more platelet adhesion which leads to fibrin formation if there is no heparin in the system [1]. The anticoagulant heparin prevents clot formation by increasing the action of antithrombin-III, an inhibitor of thrombin, and therefore inhibits the conversion of fibrinogen to fibrin. Thrombin inhibition is dose related and heparin is rapidly metabolized, thus the heparin effect can be titrated to any desired level by adjusting a continuous infusion. Our approach to anticoagulation with CAVH is derived from the method of Kramer [2], combined with our experience with prolonged extracorporeal circuits like ECMO [3].

Keywords

Activate Partial Thromboplastin Time Activate Clotting Time Heparin Therapy Thrombin Clotting Time Heparin Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bartlett RH, Andersen JC (1982) Blood-surface interactions: an overview. In: Stanley JC, Burkel WE, Lindenauer SM, Bartlett RH, Turcotte JC (eds) Biologie and synthetic vascular prostheses. Grüne and Stratton, New York, pp 63–81Google Scholar
  2. 2.
    Kramer P, Schräder J, Bohnsack W et al. (1981) Continuous arteriovenous hemofiltration: a new kidney replacement therapy. Proc Eur Dial Transplant Assoc 18: 743PubMedGoogle Scholar
  3. 3.
    Fong SW, Burns NE, Williams G, Woldenski C, Gazzaniga AB, Bartlett RH (1974) Changes in coagulation and platelet function during prolonged extracorporeal circulation in sheep and man. Trans Am Soc Artif Intern Organs 20: 239–247Google Scholar
  4. 4.
    Roohk HV, Pick J, Hill R, Hung E, Bartlett RH (1976) Kinetics of fibrinogen and platelet adherence to biomaterials. Trans Am Soc Artif Intern Organs 22: 1–7PubMedGoogle Scholar
  5. 5.
    Congdon JE, Kardinal CG, Wallin JD (1976) Monitoring heparin therapy in hemodialysis. JAMA 226: 1529–1531CrossRefGoogle Scholar
  6. 6.
    Lee RI, White PD (1913) A clinical study of the coagulation time of blood. Am J Med Sei 145: 495–503CrossRefGoogle Scholar
  7. 7.
    Basu D, Gallus A, Hirsh J, Cade J (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287: 324–327PubMedCrossRefGoogle Scholar
  8. 8.
    Penner JA (1974) Experience with the thrombin clotting time assay for measuring heparin activity. Am J Clin Pathol 61: 645–653PubMedGoogle Scholar
  9. 9.
    Brandt JT, Triplett DA (1981) Laboratory monitoring of heparin. Am J Clin Pathol 76: 530–537PubMedGoogle Scholar
  10. 10.
    Quick AJ (1966) Hemorrhagic diseases and thromboses. Lea and Febiger, PhiladelphiaGoogle Scholar
  11. 11.
    Baden JP, Sonnenfield M, Ferlic RM, Seilers RD (1971) The BaSon test: a rapid bedside test for control of heparin therapy. Surg Forum 22: 172–174PubMedGoogle Scholar
  12. 12.
    Kurec AS, Morris NW, Davey FR (1979) Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy. Ann Clin Lab Sei 9: 494–500Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • K. Koorejian
  • R. H. Bartlett
  • J. London

There are no affiliations available

Personalised recommendations